Enliven Therapeutics, Inc.

NASDAQ:ELVN

Biotechnology

Healthcare
$44.89 -0.27%

-$0.12 today

Market cap
$3.30B
Beta
0.40
P/E (TTM)
-28.4
EPS (TTM)
-$1.57
52W Low $14.79High $48.53

Volume 0.75M

Average 1.35M

ELVN EBITDA Margin

EBITDA as a percentage of revenue.

No reported EBITDA Margin figures are available to summarize.

EBITDA Margin history

Percent of revenue · from the income statement

No EBITDA Margin data reported for this period type.

EBITDA Margin vs competitors

How ELVN compares with its peers on the latest reported figures

ELVN Competitors Peer median
EBITDA Margin for ELVN and competitors
Company Period LTM level YoY 3-year change
EXELExelixis, Inc.LTM Jul 202643.0% +6.3 pp+23.9 pp
INCYIncyte CorporationLTM Jun 202635.5% +6.0 pp+16.6 pp
NUVBNuvation Bio Inc.LTM Jun 2026-74.8% +1326.6 pp—
SNDXSyndax Pharmaceuticals, Inc.LTM Mar 2026-74.8% +669.1 pp—
RLAYRelay Therapeutics, Inc.LTM Jun 2026-2742.3% +927.4 pp+20440.0 pp
ELVNEnliven Therapeutics, Inc.FY2025— ——
RVMDRevolution Medicines, Inc.FY2025— ——
TYRATyra Biosciences, Inc.FY2025— ——
ORICORIC Pharmaceuticals, Inc.FY2025— ——
AVBPArriVent BioPharma, Inc. Common StockFY2025— ——
CGEMCullinan Therapeutics, Inc.FY2025— ——
Peer median (excluding ELVN) -74.8%+669.1 pp+23.9 pp

Competitors are the stored peer set for ELVN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00000
Cost of Revenue0000263K
Gross Profit0000(263K)
Gross Margin—————
Research & Development20.47M31.02M64.57M80.78M85.86M
Selling, General & Admin4.29M7.77M18.96M23.78M33.8M
Operating Expenses24.76M38.79M83.53M104.55M119.4M
Depreciation & Amortization115K215K297K317K263K
EBITDA(24.63M)(37.45M)(71.29M)(88.48M)(103.43M)
EBITDA Margin—————
Operating Income(24.76M)(38.79M)(83.53M)(104.55M)(119.66M)
Operating Margin—————
Interest Income22K1.13M11.97M14.89M16.01M
Interest Expense00000
Other Income / Expenses22K1.13M11.95M15.76M15.96M
Income Before Tax(24.74M)(37.66M)(71.58M)(88.79M)(103.69M)
Pre-Tax Margin—————
Income Tax Expense000232K0
Net Income(24.74M)(37.66M)(71.58M)(89.02M)(103.69M)
Net Margin—————
EPS (Basic)(3.17)(6.03)(2.01)(1.89)(1.83)
EPS (Diluted)(3.17)(6.03)(2.01)(1.89)(1.83)
Weighted Avg Shares7.81M6.25M35.55M47.07M56.66M
Weighted Avg Shares (Diluted)7.82M6.25M35.55M47.07M56.66M

Enliven Therapeutics, Inc.

NASDAQ:ELVN

Intrinsic Alpha fair value

Locked

Current Price

$44.89

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.